Therapeutic goods regulations
|
|
|
- Jonathan Montgomery
- 9 years ago
- Views:
Transcription
1 Therapeutic goods regulations Exempt goods Schedule 5 Subregulation 12(1) Schedule 5A Subregulation 12(1A) December 1997
2 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) The TGA is a division of the Australian Government Department of Health Ageing, is responsible for regulating medicines medical devices. TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable stards of quality, safety efficacy (performance), when necessary. The work of the TGA is based on applying scientific clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines medical devices. The TGA relies on the public, healthcare professionals industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. To report a problem with a medicine or medical device, please see the information on the TGA website. Copyright Commonwealth of Australia 1997 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests inquiries concerning reproduction rights should be addressed to the Commonwealth Copyright Administration, Attorney General s Department, National Circuit, Barton ACT 2600 or posted at Therapeutic goods regulations exempt goods, December 1997 Page i
3 *Extract applicable to Therapeutic Devices Therapeutic Goods Regulations SCHEDULE 5 Subregulation 12(1) THERAPEUTIC GOODS EXEMPT FROM THE OPERATION OF PART 3 OF THE ACT Item No. Therapeutic Goods 1 therapeutic goods that are imported for use in the treatment of the importer or the importer's immediate family where: the goods do not contain a substance the importation of which is prohibited under the Customs Act 1901; in the case of injections that contain material of human or animal origin - the goods are the subject of an approval under section 19 of the Act, or are insulin preparations; in the case of other drugs: (i) the quantity imported in one importation is not more than 3 months' supply at the maximum dose recommended by the manufacturer; (ii) the total quantity of the drug imported for use in the treatment of the importer or the importer's immediate family in the period of 12 months ending on the day on which the latest importation occurs does not exceed 15 months' supply of the drug at the maximum dose recommended by the manufacturer; or the drugs have been approved, or are included in a class of drugs that has been approved, under regulation 5 of the Customs (Prohibited Imports) Regulations for importation into Australia; (d) if the goods are subject to Schedule 4 or Schedule 8 to the Poisons Stard - the goods are the subject of a written authority issued by a medical practitioner registered under a law of a State or Territory, except where the goods are carried by the importer as a passenger on a ship or aeroplane 2 therapeutic goods that are exported that: are not for commercial supply; do not contain a substance the exportation of which is prohibited under the Customs Act 1901; are not intended for use in clinical trials on humans 3 samples of therapeutic goods imported, exported, manufactured, or supplied for: submission to a regulatory authority; or subjection to developmental or quality control procedures; or examination, demonstration or display; or (d) subjection to analysis or laboratory testing procedures; but not for supply for therapeutic use in humans 4 goods imported solely for the purpose of export that remain subject to the control of the Customs that are not subject to manufacture in Australia 5 custom made therapeutic devices that are produced for a particular person for therapeutic application to that person, other than the following goods: therapeutic devices referred to in item 3 of Part 1 of Schedule 3; therapeutic devices referred to in an item in Part 2 of Schedule 3; electronic devices that must be programmed for each patient using those devices 6 drugs that are dispensed, or extemporaneously compounded, for a particular person for therapeutic application to that person 7 the following therapeutic devices parts of therapeutic devices: components parts of therapeutic devices intended for use in the manufacture, installation, repair or maintenance of devices that are not provided separately to the consumer as an accessory or consumable component, other than; (i) components for artificial limbs; or (ii) programmers for implantable electronic devices; or (iii) components of implantable devices that are assembled in the body; or diagnostic goods for in vitro use other than: (i) goods for home use; or (ii) goods that incorporate material of human origin; or (iii) goods supplied as a pharmaceutical benefit; or (iv) containers of a kind referred to in paragraph 7(l); or non-implantable, non-powered diagnostic tools that: (i) are not supplied in a sterile state; (ii) are not intended to monitor a physiological process; (iii) are not referred to in paragraph ; or (d) non-powered medical or dental instruments that: (i) depend on manual dexterity for their use; (ii) are not supplied in whole or in part in a sterile state; except endoscopes endoscopic accessories, flexible tubes, catheters, cannulae, fluid gas lines other instruments that introduce fluids or gases to, or remove them from, the body; or (e) manufacturing, laboratory dispensary equipment used in diagnosis or in the preparation of therapeutic goods except: (i) equipment specifically designed to process a patient's blood or other tissues for re-introduction to Incorporating Amendments to Dec Appendix 8 to DR4
4 (f) (fa) (g) (h) (i) (j) (k) (l) (m) (n) (o) (p) (q) the patient; or (ii) a bench top or portable steriliser, not permanently connected to plumbing or electrical wiring, used to sterilise medical or dental instruments; or therapeutic devices for dental use that are: (i) constructed externally to the mouth; (ii) fitted or fixed into the mouth on a temporary or permanent basis; (iii) intended for protection, or to correct an irregularity or deficiency; other than the following: (iv) devices of human or animal origin; (v) dental restorative materials; (vi) devices that, when used, are implanted directly into bone or soft tissue; (vii) therapeutic devices for dental use included in an item in Schedule 3 or 4; or therapeutic devices for dental use that are dental impression materials; non-powered devices used in general patient care, being devices that do not constitute or contribute to a specific diagnosis, monitoring or treatment of a medical condition; or furniture other than powered appliances for use in diagnosis or treatment of a medical condition; or linen bedding other than linen bedding supplied in a sterile state; or protective clothing for patients or health workers, except: (i) clothing supplied in a sterile state; or (ii) surgeon's gloves, patient examination gloves other protective gloves for the prevention of contact with body fluids or body tissue; or (iii) patient nuclear radiation shields radiation shielding apparel; or communications equipment except telemetry equipment other patient monitoring equipment that directly monitors a physiological process; or containers other than: (i) syringes; or (ii) single use containers designed for the collection, storage transfer of blood for diagnostic testing (other than single use containers recommended by the manufacturer to be used only in equipment measuring the physical properties of blood); or (iii) containers designed for the collection of blood for transfusion; or (iv) containers designed for the collection of blood for use in the manufacture of blood products or (v) containers designed for the storage of blood blood components for parenteral administration; or (vi) containers, not made of glass, designed for the storage parenteral administration of therapeutic goods (commonly referred to as large volume parenteral infusion bags ); or (vii) bags designed for the collection of fluids drained from the body of a patient (commonly referred to as drainage bags ); or therapeutic devices: (i) imported by their users before the commencement of the Act; (ii) that are still in use for administration to, or application in the treatment of, patients; or non-sterile, non-powered therapeutic devices that are: (i) medicine droppers, measures or spoons; or (ii) non-absorbent applicators; or (iii) absorbent applicators designed for use with inhalations; or non-powered orthoses or splints that do not exert traction; or non-powered hot or cold packs; or human tissue for implantation in the human body that is obtained, stored supplied without any deliberate alteration to its biological or mechanical properties by institutions the procedures of which conform with principles determined under subsection 36(1) of the Act 8 (f) disinfectants, except: (i) disinfectants included in items 5 6 of Part 2 of Schedule 3: or (ii) disinfectants included in item 16 of Part 1 of Schedule 4; or (iii) disinfectants for use with contact lenses; Therapeutic Goods Regulations SCHEDULE 5A Subregulation 12(1A) THERAPEUTIC GOODS EXEMPT FROM THE OPERATION OF PART 3 OF THE ACT SUBJECT TO CONDITIONS Item No. Therapeutic goods Conditions 1 Therapeutic goods imported into Australia that are held under the direct control of the sponsor, until the goods are: the subject of a notification under item 3; or approved for importation into Australia under subsection 19(1) of the Act the sponsor must: (i) keep records relating to the source supply of the goods; (ii) if requested by the Secretary - supply the records to the Secretary; if the goods are the subject of a notification under item 3 or an approval under subsection 19(1) of the Act - the supply of the goods must be in accordance with the notification or approval; if the goods are the subject of a notification under item 3 or an approval under subsection 19(1) of the Act are kept in a Incorporating Amendments to Dec Appendix 8 to DR4
5 warehouse in accordance with the notification or approval for a period of up to 12 months: (i) in the case of therapeutic goods other than therapeutic devices - the goods must be destroyed within 1 month of the end of that period: (ii) in the case of therapeutic devices - the devices must be destroyed or returned to the consignor of the devices within 1 month of the end of that period 1A Therapeutic goods imported into Australia held under the direct control of the sponsor, until a decision is made under section 25 or 26 of the Act in relation to the goods the sponsor must: (i) keep records relating to the source of the goods; (ii) if requested by the Secretary - supply the records to the Secretary; (iii) have lodged an application under section 23 of the Act in relation to the goods before their importation; if the goods are not registered or listed: (i) the goods must be destroyed; or (ii) in the case of therapeutic devices - the devices must be destroyed or returned to the consignor of the devices within 1 month of the decision not to register or list the devices. 2 Item 2 omitted by No Therapeutic goods used solely for experimental purposes in humans (d) (e) (f) before starting to use the goods, the sponsor must notify the Secretary: (i) in a form approved by the Secretary; (ii) in accordance with the requirements (if any) determined by the Secretary for the form of notification; that the sponsor intends to sponsor a clinical trial using specified goods; the notification must be accompanied by the relevant notification fee referred to in item 14 or 14A of Schedule 9; the approval of the goods for this purpose must be given by the sponsor (if the sponsor is conducting the trial), or by the body or organisation conducting the trial for the sponsor, having regard to the advice of the ethics committee that has, or will assume, responsibility for monitoring the conduct of the trial; the terms of the approval by the sponsor, body or organisation referred to in paragraph must be no less restrictive than the terms advised by the ethics committee; the Secretary must not, at any time: (i) have become aware that to conduct or to continue the trial would be contrary to the public interest; (ii) have directed that the trial not be conducted, or be stopped; the sponsor (if the sponsor is conducting the trial), or the body or organisation conducting the trial for the sponsor, must not receive, or have received, advice from the ethics committee that is inconsistent with the continuation of the trial. 4 Therapeutic goods that are imported by a member of a group of persons Incorporating Amendments to Dec Appendix 8 to DR4 (d) (e) (f) (g) the group must be visiting Australia to participate in a national or an international sporting event; the goods must be for use in the treatment of a member or members of that group; the importation of the goods must not be prohibited under the Customs (Prohibited Imports) Regulations; the goods must not be supplied to, or used in the treatment of, a person who is not a member of the visiting group; any portion of the goods that is unused at the end of the visit must be destroyed or removed from Australia; a member of the group must be responsible for the control custody of the goods while the group is in Australia; the person referred to in paragraph (f) must: (i) carry a list, in English, of the quantity nature of the therapeutic goods imported; (ii) for each of the goods that is not a therapeutic device - include in the list the generic name strength of the active ingredient of the goods; (iii) keep a record of the use of the goods while the group is in Australia; (iv) produce the list or the record for inspection at the request of a customs officer or a person who is an authorised officer for the purposes of a provision
6 5 Therapeutic goods, other than goods referred to in Item 3, that are: manufactured by a person: (i) under a contract between the person a private hospital; (ii) in accordance with a formulation specified by the private hospital; (iii) for use by, or in connection with, a patient of the private hospital; or manufactured by a person: (i) under a contract between the person a public hospital in a State or Territory; (ii) in accordance with a formulation specified by the public hospital; (iii) for use by, or in connection with, a patient of a public hospital in the same State or Territory; or manufactured by a person: (i) under a contract between the person a public institution; (ii) in accordance with a formulation specified by the public institution; (iii) for use by, or in connection with, a patient of the public institution of Part 5 of these Regulations there are no listed goods or registered goods that, in all relevant respects, are substantially similar to the goods; the person: (i) manufactures the goods at premises in Australia; (ii) holds a license, required by the Act, that authorises the manufacture, or a step in the manufacture, of the goods at those premises; the person notifies the Secretary, in accordance with a form approved by the Secretary, within 15 days of the end of a quarter, of: (i) the goods manufactured under the contract during that quarter; (ii) the private hospital, public hospital or public institution that entered the contract 6 Anti-D immunoglobulin the product must be imported by Commonwealth Serum Laboratories Limited ( CSL ) from Orthodiagnostic System Inc ( OSI ) in the United States of America; supply of the product in Australia must be by, or on behalf of, CSL; when supplied to the patient, the product must have with it: (i) a copy of the Patient Information that includes a explanation of the conditions under which its importation was permitted; (ii) a copy of the Product Information, applicable to the product, that is published by OSI approved by the United States Food Drug Administration; (d) the patient must give to the treating medical practitioner, in writing, adequately informed consent to the administration of the product; (e) the treating medical practitioner must retain the written consent of the patient. 7 Therapeutic goods, or parts of therapeutic goods, that form part of one of the following device kits: (d) orthopaedic fixation systems; diagnostic goods for in vitro use that are reagents, reagent products or a combination of those products; drug delivery systems in which the drug is supplied in a device that acts as a container; dental restorative systems none of the goods, or any part of the goods are separately supplied in Australia; if the component kit manufacturer are the same manufacturer the components are not separately supplied outside the kit by the kit sponsor; if the kit sponsor or the manufacturer obtains components from other manufacturers the kit manufacturer's license covers quality control of those components * Please refer to the Therapeutic Goods Regulations for complete Schedules Incorporating Amendments to Dec Appendix 8 to DR4
7 Therapeutic Goods Administration PO Box 100 Woden ACT 2606 Australia Phone: Fax:
2002 No. 618 CONSUMER PROTECTION. The Medical Devices Regulations 2002
STATUTORY INSTRUMENTS 2002 No. 618 CONSUMER PROTECTION The Medical Devices Regulations 2002 Made - - - - - 20th May 2002 Laid before Parliament 21st May 2002 Coming into force - - 13th June 2002 ARRANGEMENT
Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?
Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules? CEMO Congress, Paris, February 3rd, 2011 Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs Agenda
Application instructions
Application instructions Conformity assessment certification Version 1.4, April 2015 About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian
Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
AUSTRALIAN REGULATORY GUIDELINES FOR MEDICAL DEVICES
AUSTRALIAN REGULATORY GUIDELINES FOR MEDICAL DEVICES Version 1.0 April 2010 Version history Version Description of change Author Effective Date 1.0 Initial publication on TGA website ODBT 28 April 2010
TGA key performance indicators and reporting measures
TGA key indicators and reporting measures Regulator Performance Framework Version 1.0, May 2015 About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the
EMKI has competence in conformity assessment - on the basis of EU directives 93 /42/EEC - for companies dealing with product ranges listed below.
EMKI COMPETENCE in MD EMKI has competence in conformity assessment - on the basis of EU directives 93 /42/EEC - for companies dealing with product ranges listed below. Annex II.: EC DECLARATION OF CONFORMITY
The Regulation of Medical Devices in the UK
The Regulation of Medical Devices in the UK 1. What are the main requirements for a medical device to enter into the market and how are they regulated? Are there any licensing, marketing authorisation,
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist
CITY OF COLORADO SPRINGS TAX GUIDE MEDICAL EXEMPTIONS
CITY OF COLORADO SPRINGS TAX GUIDE MEDICAL EXEMPTIONS The City of Colorado Springs Sales and Use Tax Ordinance contains a medical exemption and definitions that, when combined, provide a variety of exemptions
Med-Info. Council Directive 93/42/EEC on Medical Devices. TÜV SÜD Product Service GmbH
Med-Info International expert information for the Medical Device industry Council Directive 93/42/E on Medical Devices Practice-oriented summary of the most important aspects and requirements contained
POLICY STATEMENT 5.17
POLICY STATEMENT 5.17 DENTAL RECORDS 1 (Including ADA Guidelines for Dental Records) 1. Introduction 1.1 Dentists have a professional and a legal obligation to maintain clinically relevant, accurate and
Australian Medical Devices Guidance Document Number XX. Custom Made Medical Devices
Australian Medical Devices Guidance Document Number XX Custom Made Medical Devices December 2008 Custom made medical devices V1.1 Page 1 of 29 Disclaimer This document is provided for guidance only. Please
Energy Products (Safety and Efficiency) Regulations 2012
Version: 10.5.2012 South Australia Energy Products (Safety and Efficiency) Regulations 2012 under the Energy Products (Safety and Efficiency) Act 2000 Contents 1 Short title 2 Commencement 3 Interpretation
GUIDELINES ON COMPOUNDING OF MEDICINES. March 2015. PharmBA1502 01
GUIDELINES ON COMPOUNDING OF MEDICINES March 2015 PharmBA1502 01 Contents Who needs to use these guidelines?............................................. 3 Introduction..........................................................
Legislation and Regulation RHPA: Scope of Practice, Controlled Acts Model
REFERENCE DOCUMENT Legislation and Regulation RHPA: Scope of Practice, Controlled Acts Model Table of Contents Introduction 3 Scope of Practice Statement 3 Nursing s Scope of Practice Statement 3 Controlled
Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC
Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC August 2013 Contents 1 Introduction...3 2 Scope of the directive...3 2.1 What is an in vitro diagnostic medical device?... 3 2.2 Specimen
2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC
2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC Objectives 1. Review the changes to the pharmacy practice act related to sterile compounding. 2. Understand the role of the
Investigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
8 OPERATING THEATRE AND ANAESTHETIC SERVICES
1 8 OPERATING THEATRE AND ANAESTHETIC SERVICES OVERVIEW OF OPERATING THEATRE AND ANAESTHETIC SERVICES Services in the operating theatre and anaesthetic services carry high risk. It is essential that there
GUIDELINES ON MEDICAL DEVICES. IVD GUIDANCES : Borderline issues A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single Market : regulatory environment, standardisation and New Approach Pressure equipment, medical devices, metrology MEDDEV. 2.14/1 rev. 1 January
Pharmacy Policy (General)
WORKSAFE VICTORIA Pharmacy Policy (General) WorkSafe can pay the reasonable costs of medications and other pharmacy items required as a result of a work-related injury or illness in accordance with Victorian
Conformity assessment certification
TGA use only This form, when completed, will be classified as 'For official use only'. For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA
GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES
Foreword GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES These guidance notes do not aim to be a definite interpretation of National Laws and/or regulations and are for guidance purpose only.
Ch. 109 NURSING SERVICES 28 CHAPTER 109. NURSING SERVICES GENERAL PROVISIONS
Ch. 109 NURSING SERVICES 28 CHAPTER 109. NURSING SERVICES GENERAL PROVISIONS Sec. 109.1. Principle. 109.2. Director of nursing services. 109.3. Assistants to director of nursing services. 109.4. Professional
Guideline on the Controlled Acts and Delegation
Guideline on the Controlled Acts and Delegation C o l l e g e o f O c c u p a t i o n a l T h e r a p i s t s o f O n t a r i o June 2000 Introduction The College receives numerous practice calls seeking
GUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES
GUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES Foreword This guidance document is informative and advisory and has no legal authority. Individual national enforcement authorities are bound
(OJ L 169, 12.7.1993, p. 1)
1993L0042 EN 11.10.2007 005.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning
ALASKA. Downloaded January 2011
ALASKA Downloaded January 2011 7 AAC 12.255. SERVICES REQUIRED A nursing facility must provide nursing, pharmaceutical, either physical or occupational therapy, social work services, therapeutic recreational
COMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
Health Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
Part 3 Medical Officer (MO) Work Level Standards
Part 3 Medical Officer (MO) Work Level Standards MEDICAL OFFICER-CLASSES 1 6 GROUP STANDARD The work of positions in this group involves the application of professional medical knowledge and experience
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical
2.3. The management in each HCF shall be responsible for ensuring good waste management practices in their premises.
1. PURPOSE Health-care activities lead to production of medical waste that may lead to adverse health effects. Most of this waste is not more dangerous than regular household waste. However, some types
How To Inspect A Blood Bank
Site visit inspection report on compliance with HTA minimum standards Belfast Cord Blood Bank HTA licensing number 11077 Licensed for the procurement, processing, testing, storage, distribution and import/export
MEDICAL DEVICE GUIDANCE
May 2014 MEDICAL DEVICE GUIDANCE GN-23: Guidance on Labelling for Medical Devices PREFACE This document is intended to provide general guidance. Although we have tried to ensure that the information contained
Summary of the role and operation of NHS Research Management Offices in England
Summary of the role and operation of NHS Research Management Offices in England The purpose of this document is to clearly explain, at the operational level, the activities undertaken by NHS R&D Offices
Dental Practice (General) Regulations 2007
Historical version: 1.7.2009 to 31.1.2010 South Australia Dental Practice (General) Regulations 2007 under the Dental Practice Act 2001 Contents 1 Short title 3 Interpretation 4 Exempt provider 5 Representative
The Act on Medical Devices
The Act on Medical Devices The Act on Medical Devices of 2 nd August 1994 (Federal Law Gazette I, p. 1963), in the version of 7 th August 2002 (Federal Law Gazette I, p. 3146), last amended by Article
APES 230 Financial Planning Services
APES 230 Financial Planning Services Prepared and issued by Accounting Professional & Ethical Standards Board Limited ISSUED: April 2013 Copyright 2013 Accounting Professional & Ethical Standards Board
MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.
MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET Good Health. Good Business. Great Schools. MESSA Saver Rx Prescription Drug Program The MESSA Saver Rx Prescription Drug Program is made available by a Group
"Act" means the National Health Act, 2003 (Act No 61of 2003);
142 No.35099 GOVERNMENT GAZETTE, 2 MARCH 2012 No. R. 183 2 March 2012 NATIONAL HEALTH ACT, 2003 REGULATIONS'RELATING TO STEM CELL BANKS The Minister of Health has, in terms of section 68 of the Health
AN ACT RELATING TO DENTISTRY; CHANGING THE LICENSING OF DENTISTS AND DENTAL HYGIENISTS BY CREDENTIAL; EXPANDING THE SCOPE OF PRACTICE OF DENTAL HYGIENISTS. BE IT ENACTED BY THE LEGISLATURE OF THE STATE
Medical Devices: CE Marking Step-by Step
Medical Devices: CE Marking Step-by Step Sylvia Mohr Standards Specialist U.S. Mission to the European Union 1 Introduction CE marking in 8 Steps Overview intended purpose - technical documentation classification
PROPOSED AMENDMENTS NURSES (REGISTERED) AND NURSE PRACTITIONERS REGULATION. Health Professions Act
Health Professions Act NURSES (REGISTERED) AND NURSE PRACTITIONERS REGULATION PROPOSED AMENDMENTS TO B.C. REG. 284/2008 abc abc text to be removed text to be added Contents 1 Definitions 2 College name
H4235 An Act relative to pharmacy practice in the Commonwealth
H4235 An Act relative to pharmacy practice in the Commonwealth Summary THE BOARD OF REGISTRATION IN PHARMACY SECTIONS 2 & 3. The Board of Registration in Pharmacy is expanded to include 13 individuals,
Presented by Rosemarie Bell 24 April 2014
Global Good Manufacturing Practice A Comparability Study to Link Good Manufacturing Practice Standards for World Wide Compliance Within the Cellular Therapy Industry Presented by Rosemarie Bell 24 April
Disposal Schedule for Patient and Medical Records Disposal Authorisation No. DS 20
Disposal Schedule for Patient and Medical Records Disposal Authorisation No. DS 20 Department of Health and Human Services TABLE OF CONTENTS INTRODUCTION page 5 Archives legislation page 5 Schedule elements
Health and Safety (Sharp Instruments in Healthcare) Regulations 2013
Health and Safety (Sharp Instruments in Healthcare) Regulations 2013 Guidance for employers and employees HSE information sheet Health Services Information Sheet 7 This information sheet is for healthcare
Licence condition handbook
Licence condition handbook January 2016 Office for Nuclear Regulation page 1 of 24 The standard licence conditions attached to nuclear site licences Introduction This booklet has been produced as an aide-memoire
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
CE-Marked Product List (MDD)
CE-Marked Product List (MDD) On March 21st the revised Directive 93/42/EEC concerning medical devices which includes the amendment M5 Directive 2007/47/EC of the European Parliament and of the Council
THE DISPOSAL OF HEALTHCARE WASTE BY NHS GRAMPIAN FROM ACUTE HOSPITAL WARDS
THE DISPOSAL OF HEALTHCARE WASTE BY NHS GRAMPIAN FROM ACUTE HOSPITAL WARDS Arrangements for the Collection and Disposal of Healthcare Waste NHS Grampian provides a range of healthcare waste disposal services
CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION
CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed
Charities and Trustee Investment (Scotland) Act 2005
Charities and Trustee Investment (Scotland) Act 2005 (asp 10) Section Charities and Trustee Investment (Scotland) Act 2005 2005 asp 10 1 Office of the Scottish Charity Regulator 2 Annual reports CONTENTS
Ambulatory Surgical Centers Frequently Asked Questions
Ambulatory Surgical Centers Frequently Asked Questions Index Top General Definitions Compliance with State Licensure Laws Governing Body and Management Surgical Services Quality Assessment and Performance
ARKANSAS. Downloaded January 2011
ARKANSAS Downloaded January 2011 302 GENERAL ADMINISTRATION 302.11 Pharmacies operated in nursing homes shall be operated in compliance with Arkansas laws and shall be subject to inspection by personnel
The Practice Standards for Medical Imaging and Radiation Therapy. Sonography Practice Standards
The Practice Standards for Medical Imaging and Radiation Therapy Sonography Practice Standards 2015 American Society of Radiologic Technologists. All rights reserved. Reprinting all or part of this document
Privacy fact sheet 17
Privacy fact sheet 17 Australian Privacy Principles January 2014 From 12 March 2014, the Australian Privacy Principles (APPs) will replace the National Privacy Principles Information Privacy Principles
APPENDIX A GUIDANCE DOCUMENT
APPENDIX A GUIDANCE DOCUMENT Infectious Substances International Civil Aviation Organization Technical Instructions for the Safe Transport of Dangerous Goods by Air, 2005-2006 Note: This guidance document
Prescription Drug Plan
Prescription Drug Plan The prescription drug plan helps you pay for prescribed medications using either a retail pharmacy or the mail order program. For More Information Administrative details and procedures
Manual: Policies Document ID: PI013 Date Created: Jun 08 Section: Investigator No. Pages: 7 Review Date: Aug 15 Future Review Date: Aug 17
P0LICYI013 PREGNANCY AND SEXUAL HEALTH POLICY Manual: Policies Document ID: PI013 Date Created: Jun 08 Section: Investigator No. Pages: 7 Review Date: Aug 15 Future Review Date: Aug 17 PURPOSE To describe
Guidelines for dispensing of medicines 6585 08/10
for dispensing of medicines 6585 08/10 for dispensing of medicines Contents Introduction 1 Who needs to use these guidelines? 1 Summary of guidelines 1 1 1 Dispensing precaution safety of prescriptions
How To Know If A Mobile App Is A Medical Device
The Regulation of Medical Device Apps Prepared for West of England Academic Health Science Network and University of Bristol June 2014 June 2014 1 Table of Contents 1 Purpose...3 2 Scope...3 3 The Regulation
Rail Safety (Alcohol and Drug Testing) Regulations 2008
Historical version: 29.9.2008 to 19.1.2013 Regulations revoked South Australia Rail Safety (Alcohol and Drug Testing) Regulations 2008 under the Rail Safety Act 2007 Contents 1 Short title 2 Commencement
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
Legal and governance framework
Annex A Legal and governance framework This annex is a brief guide to the legal and governance framework relevant to research in the UK. It is not intended to be a comprehensive statement of the law or
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
A BILL for AN ACT. Serial 270 Volatile Substance Abuse Prevention Bill 2004 Ms Scrymgour
Serial 270 Volatile Substance Abuse Prevention Bill 2004 Ms Scrymgour A BILL for AN ACT to provide for the prevention of volatile substance abuse and the protection of individuals and communities from
Draft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
Introduction. Definition
DIRECTIVES FOR PRIVATE AMBULATORY SURGICAL CENTRES PROVIDING AMBULATORY SURGERY: REGULATION 4(1) OF THE PRIVATE HOSPITALS AND MEDICAL CLINICS REGULATIONS [CAP 248, Rg 1] I Introduction 1 These directives
03 PHARMACY TECHNICIANS
03 PHARMACY TECHNICIANS 03-00 PHARMACY TECHNICIANS REGISTRATION/PERMIT REQUIRED 03-00-0001 DEFINITIONS: A. PHARMACY TECHNICIAN: This term refers to those individuals identified as Pharmacist Assistants
The Practice Standards for Medical Imaging and Radiation Therapy. Radiography Practice Standards
The Practice Standards for Medical Imaging and Radiation Therapy Radiography Practice Standards 2015 American Society of Radiologic Technologists. All rights reserved. Reprinting all or part of this document
Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
Australian Transport Council. National Standard for the Administration of Marine Safety SECTION 4 SURVEYS OF VESSELS
Australian Transport Council National Standard for the Administration of Marine Safety SECTION 4 SURVEYS OF VESSELS Edition 1 Draft for comment issued 20 December 2005 Endorsed by the Australian Transport
AIS Sports Science/Sports Medicine Best Practice Principles
AIS Sports Science/Sports Medicine Best Practice Principles Introduction For the Australian Sports Commission (ASC) and Australian Institute of Sport (AIS), integrity in sport is paramount. Accordingly,
Drinking Water Quality Management Plan Review and Audit Guideline
Drinking Water Quality Management Plan Review and Audit Guideline This publication has been compiled by Queensland Water Supply Regulator, Department of Energy and Water Supply. State of Queensland, 2013.
How to complete the Superannuation guarantee charge statement quarterly
USINESS Employers instructions NAT 9600-01.2006 SEGMENT AUDIENCE FORMAT PRODUCT ID How to complete the Superannuation guarantee charge statement quarterly These instructions include: n who must lodge a
REGULATION 3 PHARMACY TECHNICIANS
REGULATION 3 PHARMACY TECHNICIANS 03-00 PHARMACY TECHNICIANS REGISTRATION/PERMIT REQUIRED 03-00-0001 DEFINITIONS (a) Pharmacy technician means those individuals, exclusive of pharmacy interns, who assist
PLANT VARIETIES PROTECTION ACT (CHAPTER 232A, SECTION 54) PLANT VARIETIES PROTECTION RULES
CAP. 232A, R 1] Plant Varieties Protection Rules [2006 Ed. p. 1 PLANT VARIETIES PROTECTION ACT (CHAPTER 232A, SECTION 54) PLANT VARIETIES PROTECTION RULES Rule 1. Citation 2. Definitions 3. Fees 4. Forms
BERMUDA GOVERNMENT EMPLOYEES (HEALTH INSURANCE) (BENEFITS) ORDER 1997 BR 32 / 1997
QUO FA T A F U E R N T BERMUDA GOVERNMENT EMPLOYEES (HEALTH INSURANCE) (BENEFITS) ORDER 1997 BR 32 / 1997 [made under section 12 of the Government Employees (Health Insurance) Act 1986 and brought into
MISSISSIPPI LEGISLATURE REGULAR SESSION 2016
MISSISSIPPI LEGISLATURE REGULAR SESSION 2016 By: Representative Mims To: Public Health and Human Services HOUSE BILL NO. 1187 1 AN ACT TO AMEND SECTION 73-25-34, MISSISSIPPI CODE OF 1972, 2 TO REVISE THE
MEDICAL DEVICES SECTOR
MEDICAL DEVICES SECTOR MDS - G1 GUIDANCE FOR MEDICAL DEVICE IMPORTERS Version 2 Our mission is to ensure the safety of food; the safety, quality and efficacy of drugs; and the safety and effectiveness
Formulary notes for the List of Approved Medicines
Formulary notes for the List of Approved Medicines Last updated May 2016 Contents Introduction... 2 Formulary notes... 2 Generic listing of medicines... 2 PBS items... 2 Restrictions... 3 Applications
Road Transport (Drink Driving) Legislation Amendment Bill 2010
00 THE LEGISLATIVE ASSEMBLY FOR THE AUSTRALIAN CAPITAL TERRITORY (As presented) (Minister for Transport) Road Transport (Drink Driving) Legislation Amendment Contents Page Part Preliminary Name of Act
US Regulations for Import and Export of Cell Therapy Products
US Regulations for Import and Export of Cell Therapy Products Kurt Gunter, MD U Minnesota UCB Transplants (2001-2007)* Total units: 790 Number US banks: 19 Number non-us banks: 12 % units from non-us banks:
Final Document. Software as a Medical Device (SaMD): Key Definitions. Date: 9 December 2013. Despina Spanou, IMDRF Chair. IMDRF/SaMD WG/N10FINAL:2013
Final Document Title: Authoring Group: Software as a Medical Device (SaMD): Key Definitions IMDRF SaMD Working Group Date: 9 December 2013 Despina Spanou, IMDRF Chair This document was produced by the
Guidance Document Infectious Substances
Guidance Document Infectious Substances Note: 1. The following Guidance Document was developed by the ICAO DGP. The original ICAO document reflects references to the ICAO Technical Instructions these have
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
Combination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
